Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Common Complication With Effective Treatment Strategies

Krishnamurthy, Jairam; Tandra, Pavan K.

doi:10.1200/jop.19.00297

Cited by 1 publication

(3 citation statements)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to data from GLOBOCAN 2020 provided by the International Agency for Research on Cancer (IARC), the incidence is growing worldwide with an estimated number of 2.261.419 new cases per year, while average mortality is constantly decreasing, Pharmaceuticals 2023, 16, 550 2 of 27 accounting for 684.996 deaths, mainly thanks to the recent improvements in early detection techniques and the availability of novel therapeutic agents. [2].…”

Section: Introductionmentioning

confidence: 99%

“…According to current guidelines [16], first-line treatment is a non-hormonal therapy, such as moisturizing and lubricating vaginal creams, which appear to be useful in treating vaginal dryness and lead to an improvement in symptoms. If there is no response, local hormonal treatments are carried out: low-dose intravaginal ovules or intravaginal cream based on testosterone or DHEA.…”

Section: Introductionmentioning

confidence: 99%

“…If there is no response, local hormonal treatments are carried out: low-dose intravaginal ovules or intravaginal cream based on testosterone or DHEA. However, the problem is represented by estrogen-based creams and vaginal rings in subjects receiving aromatase inhibitor therapy because systemic absorption has also been demonstrated [16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update

Merlino¹,

D’Ovidio²,

Piccioni³

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

(1) Background: Genitourinary syndrome of menopause (GSM) is a medical condition that can affect breast cancer survivors (BCS). This is a complication that often can occur as a result of breast cancer treatment, causing symptoms such as vaginal dryness, itching, burning, dyspareunia, dysuria, pain, discomfort, and impairment of sexual function. BCS who experience these symptoms negatively impact multiple aspects of their quality of life to the point that some of them fail to complete adjuvant hormonal treatment; (2) Methods: In this systematic review of the literature, we have analyzed possible pharmacological and non-pharmacological treatments for GSM in BCS. We reviewed systemic hormone therapy, local hormone treatment with estrogens and androgens, the use of vaginal moisturizers and lubricants, ospemifene, and physical therapies such as radiofrequency, electroporation, and vaginal laser; (3) Results: The data available to date demonstrate that the aforementioned treatments are effective for the therapy of GSM and, in particular, vulvovaginal atrophy in BCS. Where possible, combination therapy often appears more useful than using a single line of treatment; (4) Conclusions: We analyzed the efficacy and safety data of each of these options for the treatment of GSM in BCS, emphasizing how often larger clinical trials with longer follow-ups are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%